Tuesday, 22 Oct 2019

You are here

Biologics Do Not Increase Melanoma Risk

Rheumatoid arthritis (RA) patients have a higher risk of certain cancers (e.g., skin, lung, lymphoma).  At issue is whether the newer agents modify this risk appreciably. This issue has been intensively studied and the data is clear that biologic agents do not increase the risk of lymphoma or solid tumors over that seen with active inflammatory RA alone.

Yet there is concern that some uncommon cancers may not have been well studied. A UK registry showed that while TNF inhibitor (TNFi) treated patients had a lower risk of cancer recurrence compared to DMARD treated patients, a small subset with melanoma were more likely to recurr on the TNFi compared to the DMARD.

The effect of TNFi and other biologics on melanoma risk was analyzed by Mercer et al, who pooled the data from 11 biologic registers from nine European countries.  They analyzed  130315 RA patients, followed for 579, 983 pt-yrs, until the occurrence of their first invasive melanoma.

They identified 287 melanomas and found no difference in melanoma risk when looking at the biologic-naïve, TNFi and rituximab-exposed patients (SIRS were 1.1 (95% CI 0.9 to 1.4), 1.2 (0.99 to 1.6) and 1.3 (0.6 to 2.6), respectively).

Similarly the melanoma risk in tocilizumab and abatacept-exposed patients were also not significantly increased. 

This large European collaborative project did not confirm an overall increased risk of melanoma following exposure to TNFi or other biologic agents.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Joint Injections: Are They Worth the Risk?

Intra-articular injections of corticosteroids for relief of the pain of hip or knee osteoarthritis (OA) may have adverse long-term consequences, researchers suggested.

Hydroxychloroquine Blood Levels May Predict Future Retinopathy

A study of 527 patients receiving daily hydroxychloroquine (HCQ) concluded that hydroxychloroquine blood levels may predict future HCQ retinopathy.

This study assessed whether lower HCQ dosing, as recommended by the 2016 American Academy of Ophthalmology (AAO) guidelines (less than 5 mg/kg), would favorably affect retinopathy outcomes.

Arthritis Foundation Releases First CBD Guidance for Adults With Arthritis

As the leading organization for people with arthritis, the Arthritis Foundation has just released the first CBD guidance for adults with arthritis. CBD, or cannabidiol, a plant-based compound, has become popular among people with arthritis seeking to ease chronic joint pain.

Persistent Inflammatory Arthritis After Immune Checkpoint Inhibitors

Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies, showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.